Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danshenfentong, also recorded as **DSFTP** and **丹参酚酮片**, is an oral tablet-form traditional Chinese medicine or natural-product drug candidate being developed by Beijing Baotainingtang Biotechnology for stable angina pectoris associated with coronary heart disease and the traditional Chinese medicine syndrome of heart-blood stasis. A registered Chinese Phase II randomized, double-blind, placebo-controlled, multicenter study evaluated several oral dose levels over 8 weeks. The publicly available registry information does not identify a defined molecular composition, pharmacologic target, or validated molecular mechanism. ([yscro.com](https://www.yscro.com/index.php/cde/7e66ebd31f55aae1bf3e69271d1db65e.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danshenfentong.